Further analysis indicated that lipid transport regulating factor VEGF-B and the pro-inflammatory cytokine IL-17A were closely involved in DKD progression, indicating them to be the potential targets for DKD treatment. This evidence concerns the gene IL17A and diabetic kidney disease.